Artwork

Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 905: Oseltamivir (Tamiflu) for Influenza

2:37
 
Share
 

Manage episode 420532993 series 2942787
Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Contributor: Aaron Lessem MD

Educational Pearls:

  • Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza

  • Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)

    • Benefit only occurs if taken within 48 hours of symptom onset

    • Must be taken for 5 days

  • A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization

    • No reduction in hospitalizations with oseltamivir in patients over the age of 12

    • No difference in high-risk patients over the age of 65 or those with comorbidities

      • The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations

  • Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms

    • The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness

References

1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699

2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545

Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit

  continue reading

1054 episodes

Artwork
iconShare
 
Manage episode 420532993 series 2942787
Content provided by medicalminute and Emergency Medical Minute. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by medicalminute and Emergency Medical Minute or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Contributor: Aaron Lessem MD

Educational Pearls:

  • Oseltamivir (Tamiflu) is an antiviral medication used commonly to treat influenza

  • Trials show that the medication reduces the duration of illness by less than 1 day (~16 hours in one systematic review)

    • Benefit only occurs if taken within 48 hours of symptom onset

    • Must be taken for 5 days

  • A 2024 meta-analysis reviewed 15 randomized-controlled trials for the risk of hospitalization

    • No reduction in hospitalizations with oseltamivir in patients over the age of 12

    • No difference in high-risk patients over the age of 65 or those with comorbidities

      • The authors note that the confidence interval in these populations is wide, indicating a need for subsequent studies in high-risk populations

  • Oseltamivir is associated with adverse effects including nausea, vomiting, and neurologic symptoms

    • The risk of adverse effects may outweigh the benefits of a small reduction in the duration of illness

References

1. Hanula R, Bortolussi-Courval É, Mendel A, Ward BJ, Lee TC, McDonald EG. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients with Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024;184(1):18-27. doi:10.1001/jamainternmed.2023.0699

2. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;348(April):1-18. doi:10.1136/bmj.g2545

Summarized by Jorge Chalit, OMSII | Edited by Meg Joyce & Jorge Chalit

  continue reading

1054 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide